SCHEMBL3222037

SCHEMBL3222037

Cc1cccc(C(O)(C(=O)OCC2C3C[N+](C)(C)CC23)c2ccccc2)c1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 12/20 0.45
CHRM3 P20309 12/20 0.45
CYP2D6 P10635 4/20 0.45
KCNH2 Q12809 3/20 0.45
LMNA P02545 3/20 0.45
SLC6A4 P31645 2/20 0.45
CYP2C19 P33261 1/20 0.45
CHRM1 P11229 4/20 0.44
CHRM4 P08173 2/20 0.44
CHRM5 P08912 2/20 0.44
SLC22A1 O15245 1/20 0.44
HRH1 P35367 1/20 0.42
RAB9A P51151 1/20 0.41
ALDH1A1 P00352 1/20 0.40
MEN1 O00255 1/20 0.39
POLB P06746 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4620005 0.84 ALDH1A1 (0.48) CHRM2CHRM3LMNACHRM1CHRM4
SCHEMBL4878736 0.81 LMNA (0.43) CHRM2CHRM3LMNASLC6A4CHRM1
SCHEMBL3210034 0.79 CHRM2 (0.49) CHRM2CHRM3CYP2D6KCNH2LMNA
SCHEMBL3213540 0.78 CHRM3 (0.46) CHRM2CHRM3CYP2D6KCNH2LMNA
SCHEMBL3224771 0.75 CHRM2 (0.47) CHRM2CHRM3CYP2D6KCNH2LMNA
SCHEMBL4190777 0.74 LMNA (0.41) CHRM2CHRM3CYP2D6KCNH2LMNA
SCHEMBL3226484 0.74 CHRM3 (0.44) CHRM2CHRM3CYP2D6KCNH2LMNA
SCHEMBL4190902 0.73 CHRM3 (0.56) CHRM2CHRM3CHRM1ALDH1A1
SCHEMBL19770175 0.73 CHRM3 (0.82) CHRM2CHRM3CHRM1HRH1
SCHEMBL19770179 0.73 LMNA (0.52) CHRM2CHRM3CYP2D6KCNH2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100056496-A1 MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2010-03-04 US claimed
EP-2059505-A2 MUSCARINIC RECEPTOR ANTAGONISTS Ranbaxy Laboratories Limited (IN) 2009-05-20 EP claimed
WO-2008029349-A2 MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2008-03-13 WO claimed
US-20100056496-A1 MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2010-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056496-A1 MUSCARINIC RECEPTOR ANTAGONISTS CHRM3, CHRM5, CHRM2 CHRM2 3/4885CHRM3 1/4885CYP2D6 316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.